Expression of serum Sestrin2 in acute ST-segment elevation myocardial infarction and its relationship with ischemia-reperfusion injury

doi:10.11958/20220813

Abstract

CLC Number:

R542.2+2

Figures/Tables 5

References 17

[1]	FRAMPTON J, DEVRIES J T, WELCH T D, et al. Modern management of ST-segment elevation myocardial infarction[J]. Curr Probl Cardiol, 2020, 45(3):100393. doi:10.1016/j.cpcardiol.2018.08.005.
[2]	LYU S, LIU H, WANG H. The interplay between autophagy and NLRP3 inflammasome in ischemia/reperfusion injury[J]. Int J Mol Sci, 2021, 22(16):8773. doi:10.3390/ijms22168773.
[3]	PICKELL Z, WILLIAMS A M, ALAM H B, et al. Histone deacetylase inhibitors:a novel strategy for neuroprotection and cardioprotection following ischemia/reperfusion injury[J]. J Am Heart Assoc, 2020, 9(11):e016349. doi:10.1161/JAHA.120.016349.
[4]	PANISELLO-ROSELLO A, ROSELLO-CATAFAU J. Molecular mechanisms and pathophysiology of ischemia-reperfusion injury[J]. Int J Mol Sci, 2018, 19(12):4093. doi:10.3390/ijms 19124093.
[5]	KISHIMOTO Y, KONDO K, MOMIYAMA Y. The protective role of sestrin2 in atherosclerotic and cardiac diseases[J]. Int J Mol Sci, 2021, 22(3):1200. doi:10.3390/ijms22031200.
[6]	郭明, 赵博, 雷少青, 等. Sestrin2/一磷酸腺苷活化的蛋白激酶介导的细胞自噬在糖尿病大鼠心肌缺血再灌注损伤中的作用及叔丁基对苯二酚预处理的保护作用[J]. 中华糖尿病杂志, 2017, 9(6):382-387.
	GUO M, ZHAO B, LEI S Q, et al. Sestrin2/adenosine monophosphate activated protein kinase regulated autophagy pathway in myocardial ischemia-reperfusion injury in diabetic rats and the protective effect of tert-butyl hydroquinone[J]. Chin J Diabet, 2017, 9(6):382-387. doi:10.3760/cma.j.issn.1674-5809.2017.06.010.
[7]	中华医学会心脏病学会, 中国心脏病学杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10):766-783.
	SOCIETY OF CARDIOLOGY, C M A,EDITORIAL BOARD OF CHIN J CARDIOL. 2019 Chinese Society of Cardiology(CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chin J Cardiol, 2019, 47(10):766-783. doi:10.3760/cma.j.issn.0253-3758.2019.10.003.
[8]	张英, 王亚柱, 张皓然, 等. 心肌缺血再灌注损伤不同表现形式的临床研究[J]. 中国医药导报, 2019, 16(23):64-68.
	ZHANG Y, WANG Y Z, ZHANG H R, et al. Clinical study on different manifestations of myocardial ischemia-reperfusion injury[J]. Chin Med Herald, 2019, 16(23):64-68.
[9]	BHATT D L, LOPES R D, HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes:A review[J]. JAMA, 2022, 327(7):662-675. doi:10.1001/jama.2022.0358.
[10]	ZHENG J, CHEN P, ZHONG J, et al. HIF-1α in myocardial ischemia-reperfusion injury(Review)[J]. Mol Med Rep, 2021, 23(5):352. doi:10.3892/mmr.2021.11991.
[11]	ZHANG M L, PENG W, NI J Q, et al. Recent advances in the protective role of hydrogen sulfide in myocardial ischemia/reperfusion injury:a narrative review[J]. Med Gas Res, 2021, 11(2):83-87. doi:10.4103/2045-9912.311499.
[12]	WANG P, ZHAO Y, LI Y, et al. Sestrin2 overexpression attenuates focal cerebral ischemic injury in rat by increasing Nrf2/HO-1 pathway-mediated angiogenesis[J]. Neuroscience, 2019, 410(7):140-149. doi:10.1016/j.neuroscience.2019.05.005.
[13]	SUN W, WANG Y, ZHENG Y, et al. The emerging role of sestrin2 in cell metabolism, and cardiovascular and age-related diseases[J]. Aging Dis, 2020, 11(1):154-163. doi:10.14336/AD.2019.0320.
[14]	CHE X, CHAI J, FANG Y, et al. Sestrin2 in hypoxia and hypoxia-related diseases[J]. Redox Rep, 2021, 26(1):111-116. doi:10.1080/13510002.2021.1948774.
[15]	PAN C, CHEN Z, LI C, et al. Sestrin2 as a gatekeeper of cellular homeostasis:physiological effects for the regulation of hypoxia-related diseases[J]. J Cell Mol Med, 2021, 25(12):5341-5350. doi:10.1111/jcmm.16540.
[16]	庞旭阳, 郝晓静, 郭宏盛, 等. 急性缺血性脑卒中患者血清PRDX1、Sestrin2水平与病情及预后的关系[J]. 中国现代医学杂志, 2021, 31(9):51-55.
	PANG X Y, HAO X J, GUO H S, et al. Correlation of serum Sestrin 2 and PRDX1 with prognosis of patients with acute ischemic stroke[J]. Chin J Mod Med, 2021, 31(9):51-55. doi:10.3969/j.issn.1005-8982.2021.09.010.
[17]	刘英存, 李飞, 黄毅, 等. Sestrin2蛋白通过Nrf2/HO-1信号通路保护大鼠心肌细胞缺氧复氧损伤[J]. 第三军医大学学报, 2020, 42(15):1536-1542.
	LIU Y C, LI F, HUANG Y, et al. Sestrin2 protects rat cardiomyocytes from hypoxia-reoxygenation injury through Nrf2/HO-1 signaling pathway[J]. Acta Acad Med Mil Tert, 2020, 42(15):1536-1542. doi:10.16016/j.1000-5404.202003201.

组别	n	Sestrin2（μg/L）	MDA（μmol/L）	SOD（U/L）
对照组	50	6.53±2.01	3.97±1.05	98.87±15.87
STEMI组	124	10.36±3.18	5.32±1.56	72.32±13.12
t		7.896^＊＊	5.622^＊＊	11.354^＊＊

组别	n	Sestrin2（μg/L）	MDA（μmol/L）	SOD（U/L）
对照组	50	6.53±2.01	3.97±1.05	98.87±15.87
STEMI组	124	10.36±3.18	5.32±1.56	72.32±13.12
t		7.896^＊＊	5.622^＊＊	11.354^＊＊

组别		n	性别（男/女）			年龄（岁）			体质量指数（kg/m²）			高血压
非IRI组		52	32/20			57.17±8.51			22.12±1.49			31（59.62）
IRI组		72	44/28			59.01±8.76			22.19±1.61			46（63.89）
χ²或t			0.002			1.168			0.246			0.234
组别	糖尿病			高脂血症			心绞痛史			发病到治疗时间（h）				D to B （min）
非IRI组	10（19.23）			19（36.54）			15（28.85）			3.32±1.09				50.34±8.62
IRI组	18（25.00）			28（38.89）			24（33.33）			3.69±1.28				53.04±9.25
χ²或t	0.575			0.071			0.282			1.688				1.650
组别	cTnI （μg/L）				LVEF			Sestrin2 （μg/L）			MDA （μmol/L）		SOD （U/L）
非IRI组	19.86±4.52				0.63±0.07			7.84±2.67			4.53±1.29		79.95±14.96
IRI组	24.75±6.42				0.61±0.06			12.18±3.39			5.89±1.62		66.81±12.18
χ²或t	4.711^＊＊				1.707			7.670^＊＊			5.012^＊＊		5.383^＊＊

组别		n	性别（男/女）			年龄（岁）			体质量指数（kg/m²）			高血压
非IRI组		52	32/20			57.17±8.51			22.12±1.49			31（59.62）
IRI组		72	44/28			59.01±8.76			22.19±1.61			46（63.89）
χ²或t			0.002			1.168			0.246			0.234
组别	糖尿病			高脂血症			心绞痛史			发病到治疗时间（h）				D to B （min）
非IRI组	10（19.23）			19（36.54）			15（28.85）			3.32±1.09				50.34±8.62
IRI组	18（25.00）			28（38.89）			24（33.33）			3.69±1.28				53.04±9.25
χ²或t	0.575			0.071			0.282			1.688				1.650
组别	cTnI （μg/L）				LVEF			Sestrin2 （μg/L）			MDA （μmol/L）		SOD （U/L）
非IRI组	19.86±4.52				0.63±0.07			7.84±2.67			4.53±1.29		79.95±14.96
IRI组	24.75±6.42				0.61±0.06			12.18±3.39			5.89±1.62		66.81±12.18
χ²或t	4.711^＊＊				1.707			7.670^＊＊			5.012^＊＊		5.383^＊＊

指标	β	SE	Wald χ²	P	OR	OR95%CI
cTnI	0.267	0.201	1.765	0.184	1.306	0.881~1.937
Sestrin2	0.542	0.186	8.491	0.004	1.719	1.194~2.476
MDA	0.368	0.174	4.473	0.034	1.445	1.027~2.032
SOD	-0.645	0.248	6.764	0.009	0.525	0.323~0.853
常数项	0.205	0.103	3.961	0.047	1.228	-

Expression of serum Sestrin2 in acute ST-segment elevation myocardial infarction and its relationship with ischemia-reperfusion injury

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

Figures/Tables 5

References 17

Related Articles 15

Recommended Articles

Metrics

Comments

指标	AUC（95%CI）	敏感度（%）	特异度（%）	约登指数	截断值
Sestrin2	0.759（0.673~0.845）	76.39	67.31	0.437	9.41 μg/L
MDA	0.654（0.557~0.751）	56.94	73.08	0.300	5.28 μmol/L
SOD	0.671（0.575~0.767）	84.72	44.23	0.290	71.78 U/L

[1]	LIN Yiwei, WEI Tanjun, CHEN Fei, XIAO Cheng, YUAN Lie, WANG Yi. The in vivo and in vitro effects of Eriodictyol on metabolic dysfunction-associated steatotic liver disease by regulating UBA52 expression [J]. Tianjin Medical Journal, 2025, 53(9): 916-922.
[2]	CAO Zhenzhen, YE Rui, LIU Jiayao, MENG Tong, SUN Rong, XU Lingyao. Application value of serum Hsp90α combined with β2-MG detection in early diagnosis and prognosis of colorectal cancer [J]. Tianjin Medical Journal, 2025, 53(7): 756-760.
[3]	ZHANG Hanwen, LI Qiang, YANG Xuelian, YANG Hualan, JIANG Mei, HUANG Shu. Curative effect of different thrombolytic regimens on patients with ultra-early acute cerebral infarction of different characteristics [J]. Tianjin Medical Journal, 2025, 53(7): 770-775.
[4]	DING Yangjuan, XIA Shihai, XU Wei, GAO Qinghong, LIU Taotao. Research progress of oxidative stress and antioxidants in acute pancreatitis [J]. Tianjin Medical Journal, 2025, 53(4): 444-448.
[5]	FAN Huijuan, LIU Taotao, LI Nan, XIA Shihai. Mechanism and research progress of mesenchymal stem cell therapy for acute pancreatitis [J]. Tianjin Medical Journal, 2025, 53(3): 331-336.
[6]	WU Bin, YANG Zigeng, ZHANG Jing, LI Shuhong, YU Feng, WANG Jiawei, LI Cailing. Effect of naringenin on right ventricular remodeling induced by hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2025, 53(2): 129-134.
[7]	Hudagula , MA Zhenhua, LU Yan, DUAN Chunlan, LI Kai. The effect of perindopril on the NOX4/NLRP3 signaling pathway in TAA-induced liver fibrosis in rats [J]. Tianjin Medical Journal, 2025, 53(10): 1027-1032.
[8]	LIU Huan, ZHANG Qi, YAN Qikun, CAO Lu. A single-center study of the relationship between QRS duration of first medical contact and clinical endpoint in acute ST-segment elevation myocardial infarction [J]. Tianjin Medical Journal, 2025, 53(1): 71-74.
[9]	LI Peiyuan, WANG Gang, SHI Junfeng. The expression of plasma lncRNA CEBPA-AS1 and miR-139-5p in patients with acute cerebral infarction and their correlation with cognitive dysfunction [J]. Tianjin Medical Journal, 2025, 53(1): 75-79.
[10]	WANG Xinshuang, AN Yajuan, GUAN Xiuju, LI Jiao, LIU Yue, WEI Liping, QI Xin. Study of magnesium isoglycyrrhizinate in ameliorating cisplatin induced myocardial injury in rats [J]. Tianjin Medical Journal, 2024, 52(8): 809-814.
[11]	WU Bo, ZHU Zhuonong, ZHENG Lijuan, CHEN Junru. Effects of matrine on inflammation, oxidative stress and wound healing in atopic dermatitis [J]. Tianjin Medical Journal, 2024, 52(6): 566-571.
[12]	LI Min, GONG Jian, WU Weiwei, LIU Qiao. Research progress on the role of Nrf2/HO-1 pathway in psoriasis [J]. Tianjin Medical Journal, 2024, 52(5): 552-556.
[13]	XIE Youcheng, WANG Fei, XU Jin, YU Xiaohui. Research progress of SIRT1 in the pathogenesis of diabetic cardiomyopathy [J]. Tianjin Medical Journal, 2024, 52(4): 443-448.
[14]	CHEN Jing, WEI Yunjiao, LUO Chao, HUANG Lihua, CHEN Cheng, DUAN Shasha. The mechanism of Wumei pill on ulcerative colitis in mice based on Nrf2/ARE antioxidant stress pathway [J]. Tianjin Medical Journal, 2024, 52(3): 278-254.
[15]	HAO Jianling, XIN Jingjing, WANG Jing, TIAN Hong, SU Haitao. Effect of phillyrin regulating NLRP3 inflammatory pathway on exudates and lung injury in rats with acute pleurisy [J]. Tianjin Medical Journal, 2024, 52(2): 161-166.